Olema Pharmaceuticals
OLMA
113 hedge funds and large institutions have $724M invested in Olema Pharmaceuticals in 2023 Q4 according to their latest regulatory filings, with 33 funds opening new positions, 43 increasing their positions, 21 reducing their positions, and 17 closing their positions.
237% more call options, than puts
Call options by funds: $5.25M | Put options by funds: $1.56M
105% more repeat investments, than reductions
Existing positions increased: 43 | Existing positions reduced: 21
94% more first-time investments, than exits
New positions opened: 33 | Existing positions closed: 17
24% more capital invested
Capital invested by funds: $584M → $724M (+$140M)
20% more funds holding in top 10
Funds holding in top 10: 5 → 6 (+1)
16% more funds holding
Funds holding: 97 → 113 (+16)
19.29% less ownership
Funds ownership: 114.44% → 95.15% (-19%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$13.7M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$13.4M |
| 3 |
Morgan Stanley
New York
|
+$12.7M |
| 4 |
Janus Henderson Group
London,
United Kingdom
|
+$9.41M |
| 5 |
ABG
Ally Bridge Group
New York
|
+$8.86M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$27.5M |
| 2 |
SAM
Sectoral Asset Management
Montreal,
Quebec, Canada
|
-$5.62M |
| 3 |
Invesco
Atlanta,
Georgia
|
-$5.12M |
| 4 |
Acadian Asset Management
Boston,
Massachusetts
|
-$3.18M |
| 5 |
KCM
Kynam Capital Management
Princeton,
New Jersey
|
-$2.9M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
TI
126
Trexquant Investment
Stamford,
Connecticut
| – | -$138K | -11,151 | Closed |
|
|
DWA
127
Dorsey Wright & Associates
Pasadena,
California
| – | -$35.3K | -2,858 | Closed |
|
128
Ohio Public Employees Retirement System (OPERS)
Columbus,
Ohio
| – | -$35K | -2,850 | Closed |
|
129
Federated Hermes
Pittsburgh,
Pennsylvania
| – | -$12.8K | -1,035 | Closed |
|
130
Osaic Holdings
Scottsdale,
Arizona
| – | -$12 | -1 | Closed |
|
OLMA Hedge Fund Activity: Q4 2023 in Review
113 of the 6,860 institutional investors tracked by Wall St. Rank reported a position in Olema Pharmaceuticals (OLMA) for Q4 2023, worth a combined $724M — up 24% from $584M a quarter earlier.
Buyers outnumbered sellers: 33 funds opened new OLMA positions and 17 closed out — a net gain of 16 holders — while 43 added to existing stakes and 21 trimmed.
The largest buyer was BlackRock, adding an estimated $13.7M. The largest seller was Cormorant Asset Management, cutting an estimated $27.5M.
- 113 institutional investors held Olema Pharmaceuticals (OLMA) as of Q4 2023, up from 97 in Q3 2023.
- Funds reported $724M of Olema Pharmaceuticals stock for Q4 2023, up 24% quarter-over-quarter.
- 33 funds opened new Olema Pharmaceuticals positions in Q4 2023 and 17 closed out, a net change of +16 holders.
- The largest Olema Pharmaceuticals buyer in Q4 2023 was BlackRock, an estimated $13.7M added.
- The largest Olema Pharmaceuticals seller in Q4 2023 was Cormorant Asset Management, an estimated $27.5M sold.
Based on aggregated 13F filings for Q4 2023.